

**SUBSTANTIAL SHAREHOLDERS**

**SUBSTANTIAL SHAREHOLDERS**

So far as our Directors are aware, immediately following the completion of the [REDACTED], assuming the [REDACTED] are not exercised and each Preferred Share will automatically convert into one Share upon the [REDACTED] becoming unconditional, the following parties will have interests and/or short positions in the Shares or underlying Shares of our Company that (i) would fall to be disclosed to the Company and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, (ii) will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company:

Name	Nature of interest <sup>(1)</sup>	Shares held as of the date of this Document		Shares held immediately following the completion of the [REDACTED] <sup>(2)</sup>	
		<i>Number of Shares</i>	<i>Approximate percentage of shareholding</i>	<i>Number of Shares</i>	<i>Approximate percentage of shareholding</i>
Gao Tieta <sup>(3)</sup>	Interest in controlled corporation	63,263,528	45.01%	[REDACTED]	[REDACTED]%
GT HoldCo <sup>(3)(4)</sup>	Beneficial owner	63,263,528	45.01%	[REDACTED]	[REDACTED]%
OrbiMed Advisors III Limited <sup>(5)</sup>	Interest in controlled corporation	18,039,426	12.83%	[REDACTED]	[REDACTED]%
OrbiMed Asia GP III, L.P. <sup>(5)</sup>	Interest in controlled corporation	18,039,426	12.83%	[REDACTED]	[REDACTED]%
OrbiMed Asia <sup>(5)</sup>	Beneficial owner	18,039,426	12.83%	[REDACTED]	[REDACTED]%
Cuprite Gem <sup>(6)</sup>	Beneficial owner	17,062,440	12.14%	[REDACTED]	[REDACTED]%

*Notes:*

- (1) All interests stated are long positions.
- (2) The calculation is based on the total number of [REDACTED] Shares in issue immediately following the completion of the [REDACTED] and assuming that the [REDACTED] is not exercised.
- (3) GT HoldCo is wholly owned by Gao Tieta.
- (4) Pursuant to a share charge executed on June 22, 2021, GT HoldCo charged 36,892,670 Shares held by it to Credit Suisse AG, Singapore Branch, representing 26.25% and [REDACTED]% of the total issued share capital of the Company as of the Latest Practicable Date and immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised), respectively. Credit Suisse also beneficially owned 1,335,252 Shares as a result of the exercise of the CS Warrant, representing 0.95% and [REDACTED]% of the total issued share capital of the Company as of the Latest Practicable Date and immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised), respectively. For details of exercise of the CS Warrant, see “History, Reorganization and Development — [REDACTED] Investments.”

## SUBSTANTIAL SHAREHOLDERS

- (5) As of the Latest Practicable Date, OrbiMed Asia directly held 18,039,426 Preferred Shares. To the best knowledge of our Company, OrbiMed Advisors III Limited is the general partner of OrbiMed Asia GP III, L.P.; and OrbiMed Asia GP III, L.P. is the general partner of OrbiMed Asia Partners III, L.P. OrbiMed Advisors III Limited and OrbiMed Asia GP III, L.P. were therefore deemed to be interested in the Shares which are owned by OrbiMed Asia Partners III, L.P. under the SFO.
- (6) As of the Latest Practicable Date, Cuprite Gem directly held 17,062,440 Preferred Shares. To the best knowledge of our Company, Cuprite Gem is wholly owned by certain investment funds managed by their fund manager, Warburg Pincus LLC, among which, approximately 52.10% of Cuprite Gem is owned by Warburg Pincus China-Southeast Asia II (Cayman), L.P. The general partner of Warburg Pincus China-Southeast Asia II (Cayman), L.P. is Warburg Pincus (Cayman) China-Southeast Asia II GP, L.P., the general partner of which is Warburg Pincus (Cayman) China-Southeast Asia II GP LLC ("**WPC-SEA II Cayman GP LLC**"). The managing member of WPC-SEA II Cayman GP LLC is Warburg Pincus Partners II (Cayman), L.P., the general partner of which is Warburg Pincus (Bermuda) Private Equity GP Ltd.

Except as disclosed above, our Directors are not aware of any other person who will, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and each Preferred Share will automatically convert into one Share upon the [REDACTED] becoming unconditional), have any interest and/or short positions in the Shares or underlying shares of our Company which would fall to be disclosed to the Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company or any other member of our Group.